Which systemic condition is treated by the combination of alogliptin and pioglitazone?

Which systemic condition is treated by the combination of alogliptin and pioglitazone?

• A. Type II diabetes
• B. Hypertension
• C. Hyperlipidemia
• D. Type I diabetes

Answer: (A)

Both alogliptin and pioglitazone are antidiabetic medications used to improve glucose control in type 2 diabetes. Type 2 diabetes involves insulin resistance and gradually reduced insulin effectiveness. Alogliptin is a DPP-4 inhibitor that raises incretin hormones, boosting glucose-dependent insulin release and lowering glucagon after meals. Pioglitazone is a TZD that activates PPAR-γ, enhancing insulin sensitivity in muscle and fat and reducing hepatic glucose production. Using them together addresses two major problems in type 2 diabetes—impaired insulin action and inadequate insulin response—whereas they’re not used to treat type 1 diabetes (autoimmune beta-cell destruction) or primarily treat hypertension or hyperlipidemia.

Both alogliptin and pioglitazone are antidiabetic medications used to improve glucose control in type 2 diabetes. Type 2 diabetes involves insulin resistance and gradually reduced insulin effectiveness. Alogliptin is a DPP-4 inhibitor that raises incretin hormones, boosting glucose-dependent insulin release and lowering glucagon after meals. Pioglitazone is a TZD that activates PPAR-γ, enhancing insulin sensitivity in muscle and fat and reducing hepatic glucose production. Using them together addresses two major problems in type 2 diabetes—impaired insulin action and inadequate insulin response—whereas they’re not used to treat type 1 diabetes (autoimmune beta-cell destruction) or primarily treat hypertension or hyperlipidemia.